SCHEMBL4903320

SCHEMBL4903320

COc1cc(C(=O)Nc2ccc(Nc3nccc(-c4ccncc4)n3)cc2)cc(OC)c1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.61
BCR P11274 5/20 0.61
PRKCA P17252 4/20 0.58
PRKCD Q05655 2/20 0.58
PRKD3 O94806 1/20 0.58
PRKCG P05129 1/20 0.58
PRKCB P05771 1/20 0.58
LCK P06239 1/20 0.58
PRKCH P24723 1/20 0.58
PRKCI P41743 1/20 0.58
ZAP70 P43403 1/20 0.58
PRKCE Q02156 1/20 0.58
PRKCQ Q04759 1/20 0.58
PRKCZ Q05513 1/20 0.58
PRKD1 Q15139 1/20 0.58
JAK2 O60674 3/20 0.56
EGFR P00533 2/20 0.56
CDK2 P24941 1/20 0.56
PIK3CA P42336 1/20 0.56
PIK3CB P42338 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897378 0.91 ABL1 (0.64) ABL1BCRPRKCAPRKCDPRKD3
SCHEMBL4901012 0.90 PRKCA (0.74) ABL1BCRPRKCAPRKCDPRKD3
SCHEMBL4903523 0.89 ABL1 (0.62) ABL1BCRPRKCAEGFRPDGFRB
SCHEMBL4891611 0.85 MEN1 (0.60) ABL1BCRPRKCAPRKCDPRKD3
SCHEMBL6977323 0.83 CDK2 (0.77) ABL1BCRPRKCAPRKCDPRKD3
SCHEMBL4903410 0.82 ABL1 (0.69) ABL1BCRPRKCAJAK2EGFR
SCHEMBL4903186 0.82 ABL1 (0.75) ABL1BCRPRKCAPRKCDPRKD3
SCHEMBL6975909 0.81 JAK2 (0.70) PRKCAPRKCDPRKD3PRKCGPRKCB
SCHEMBL4900131 0.81 PDGFRA (0.77) ABL1BCRPRKCAEGFRPDGFRB
SCHEMBL4903101 0.81 ABL1 (0.59) ABL1BCRPRKCAPRKCDPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885BCR 2315/4885PRKCA 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.